Phase II trial of CLT 008 [purified myeloid progenitor cells] for the prevention of chemotherapy-related complications in patients with acute myeloid leukaemia.

Trial Profile

Phase II trial of CLT 008 [purified myeloid progenitor cells] for the prevention of chemotherapy-related complications in patients with acute myeloid leukaemia.

Planning
Phase of Trial: Phase II

Latest Information Update: 20 May 2014

At a glance

  • Drugs Romyelocel-L (Primary)
  • Indications Acute radiation syndrome; Febrile neutropenia; Haematological disorders; Immunocompromised infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top